ClinicalTrials.gg
Not yet recruitingNCT07846709BTB vs QTUpdated Oct 7, 2026

Bone-Patellar Tendon-Bone Versus Quadriceps Tendon Autograft for Anterior Cruciate Ligament Reconstruction: A Non-Inferiority Trial Regarding Anterior Knee Pain

An interventional study of Bone-Patellar Tendon-Bone Autograft ACL Reconstruction and Quadriceps Tendon Autograft ACL Reconstruction in Anterior Cruciate Ligament (ACL) Tear, sponsored by Hospital del Mar. Not yet recruiting. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Hospital del Mar · Not applicable, Interventional, and Treatment

How we know

Updated Oct 7, 2026Eligibility revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This prospective, randomized, single-center, non-inferiority clinical trial will compare anterior knee pain (AKP) after primary anterior cruciate ligament (ACL) reconstruction using either a bone-patellar tendon-bone autograft (BPTB) or a quadriceps tendon autograft with a bone block (BQT).

Participants will be randomly assigned in a 1:1 ratio to one of the two graft groups. The primary objective is to determine whether BPTB is non-inferior to BQT with respect to AKP, as assessed by the change in pressure pain threshold from the preoperative measurement to 12 months after surgery.

Secondary outcomes will include kneeling pain, the Kujala Anterior Knee Pain Scale, the visual analog scale (VAS) for pain, quadriceps muscle circumference, the subjective International Knee Documentation Committee (IKDC) score, magnetic resonance imaging (MRI) findings, clinical stability, complications, associated surgical procedures, and graft failure.

02

Conditions studied

  • Anterior Cruciate Ligament (ACL) Tear

Browse trials for

Keywords

  • Anterior cruciate ligament reconstruction
  • Bone-patellar tendon-bone autograft
  • Quadriceps tendon autograft
  • Anterior knee pain
  • Pressure algometry
  • Randomized clinical trial
03

In context

Lacerations

174 studies on the registry are indexed under Lacerations; 42 are open to participants now.

This study's planned enrollment of 150 is above the median of 65 across 128 interventional studies indexed under Lacerations.

Browse Lacerations studies →

Lead sponsor

Hospital del Mar is the lead sponsor of 45 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 7, 2026. See what changed

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Clinical and/or radiological diagnosis of an anterior cruciate ligament (ACL) injury with an indication for primary surgical reconstruction.

Ability to understand the study information and provide written .

Willingness to participate in the study and complete the planned clinical and radiological follow-up.

Technical feasibility of performing either a bone-patellar tendon-bone (BPTB) autograft or a quadriceps tendon autograft, as determined by the treating surgeon.

Exclusion Criteria Previous surgery on the affected knee. Previous fracture of the proximal tibia, distal femur, or patella of the affected knee.

History of patellofemoral pain syndrome, symptomatic insertional patellar tendinopathy, or symptomatic insertional quadriceps tendinopathy.

Need to harvest a graft that does not meet the predefined study specifications. Presence of a pain-amplifying condition or generalized chronic pain that could interfere with the assessment of anterior knee pain.

Psychiatric, cognitive, or mental health disorders that may impair follow-up, understanding of the study, or valid completion of questionnaires.

Medical to surgery or magnetic resonance imaging (MRI). Refusal to participate or withdrawal of informed consent.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Bone-Patellar Tendon-Bone Autograft

    Bone-Patellar Tendon-Bone Autograft Arm Participants will undergo primary anterior cruciate ligament (ACL) reconstruction using a bone-patellar tendon-bone (BPTB) autograft harvested from the central portion of the patellar tendon, with bone blocks approximately 9-10 mm in diameter and 10-20 mm in length. The graft will be implanted using the standardized arthroscopic ACL reconstruction technique routinely performed at the study center.

    Procedure: Bone-Patellar Tendon-Bone Autograft ACL Reconstruction

  • Experimental
    Quadriceps Tendon Autograft

    Quadriceps Tendon Autograft arm Participants will undergo primary anterior cruciate ligament reconstruction using a quadriceps tendon autograft with a bone block approximately 9-10 mm in diameter and 10-20 mm in length. The graft will be harvested as a partial-thickness graft using a standardized technique and implanted using the same standardized arthroscopic ACL reconstruction principles.

    Procedure: Quadriceps Tendon Autograft ACL Reconstruction

Interventions

  • ProcedureBone-Patellar Tendon-Bone Autograft ACL Reconstruction

    BPTB Autograft ACL Reconstruction Primary ACL reconstruction using an autologous bone-patellar tendon-bone graft harvested from the central patellar tendon, with bone blocks approximately 9-10 mm in diameter and 10-20 mm in length. Graft harvest and reconstruction will be performed using a standardized arthroscopic technique

  • ProcedureQuadriceps Tendon Autograft ACL Reconstruction

    Quadriceps Tendon Autograft ACL Reconstruction Primary ACL reconstruction using an autologous quadriceps tendon graft with a bone block approximately 9-10 mm in diameter and 10-20 mm in length. The graft will be harvested as a partial-thickness quadriceps tendon graft using a standardized technique and implanted arthroscopically.

06

What researchers measure

Primary outcomes

  1. Change in Pressure Pain Threshold mesured with presure algometry at the center of the Patella

    Time frame: Baseline to 12 months after surgery

07

Study locations

No study locations are listed for this record.

08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.

Of 46 non-industry interventional studies with no phase under Lacerations, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 72. This study's planned 24 months is above that.

Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 10 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 29, 2026
StartEst.
Oct 5, 2026
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2029
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
3 exclusion criteria removed; 6 criteria edited, 1 added
What changed in the criteria
  • AddedInclusion Criteria:
  • EditedTechnical feasibility of performing either a bone-patellar tendon-bone (BPTB) autograft or a quadriceps tendon autograft, as assesseddetermined by the treating surgeon.
  • EditedExclusion Criteria Previous surgery on the affected knee. Previous fracture of the proximal tibia, distal femur, or patella inof the affected knee.
  • EditedClinical historyHistory of patellofemoral pain syndrome, symptomatic insertional patellar tendinopathy, or symptomatic insertional quadriceps tendinopathy.
  • EditedPainNeed to harvest a graft that does not meet the predefined study specifications. Presence of a pain-amplifying condition or generalized chronic pain that could interfere with the assessment of anterior knee pain.
  • EditedPsychiatric, cognitive, or mental health disorders that may impair follow-up, understanding of the study, or valid completion of questionnaires.
  • EditedMedical contraindication to surgery or magnetic resonance imaging (MRI). Refusal to participate or withdrawal of informed consent.
Exclusion criteria
  • RemovedPrevious surgery on the affected knee.
  • RemovedNeed to harvest a graft that does not meet the predefined study standards.
  • RemovedRefusal to participate or withdrawal of informed consent.
Oct 7, 2026
Registered
First appeared on the registry
Sep 29, 2026
Show all 2 updates
  1. Oct 7, 2026
    Eligibility 3 exclusion criteria removed; 6 criteria edited, 1 added
    What changed in the criteria
    • AddedInclusion Criteria:
    • EditedTechnical feasibility of performing either a bone-patellar tendon-bone (BPTB) autograft or a quadriceps tendon autograft, as assesseddetermined by the treating surgeon.
    • EditedExclusion Criteria Previous surgery on the affected knee. Previous fracture of the proximal tibia, distal femur, or patella inof the affected knee.
    • EditedClinical historyHistory of patellofemoral pain syndrome, symptomatic insertional patellar tendinopathy, or symptomatic insertional quadriceps tendinopathy.
    • EditedPainNeed to harvest a graft that does not meet the predefined study specifications. Presence of a pain-amplifying condition or generalized chronic pain that could interfere with the assessment of anterior knee pain.
    • EditedPsychiatric, cognitive, or mental health disorders that may impair follow-up, understanding of the study, or valid completion of questionnaires.
    • EditedMedical contraindication to surgery or magnetic resonance imaging (MRI). Refusal to participate or withdrawal of informed consent.
    Exclusion criteria
    • RemovedPrevious surgery on the affected knee.
    • RemovedNeed to harvest a graft that does not meet the predefined study standards.
    • RemovedRefusal to participate or withdrawal of informed consent.
    + 3 other changes: verification date, description and arm descriptions
  2. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07846709
Lead sponsor
Hospital del Mar
Responsible party
Carlos Torrens (orthopedic surgeon, Hospital del Mar) — Principal investigator
First posted
Sep 29, 2026
Start date
Oct 5, 2026 (estimated)
Primary completion
Oct 2028 (estimated)
Completion
Oct 2029 (estimated)
Last update
Oct 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion